Return to homepagePandemic Pact

The Seley-Radtke group has developed a series of flexible nucleoside analogues ("fleximers") that have exhibited potent activity against epidemic (i.e. SARS and MERS), and endemic (i.e., NL63) human coronaviruses (CoVs). The Fast Grant will help advance our synthetic efforts as well as to fastrack our preclinical animal studies against SARS-CoV-2 and CoVID-19.

  • Funded by Emergent Ventures Fast Grants
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    Emergent Ventures Fast Grants

  • Principal Investigator

    Dr. Katherine Seley-Radtke

  • Research Location

    United States of America

  • Lead Research Institution

    University of Maryland

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract